Company profile

Jason Grenfell-Gardner
Incorporated in
Fiscal year end
Former names
Igi Inc, Igi Laboratories, Inc
IRS number

TLGT stock data



7 Aug 19
19 Oct 19
31 Dec 19


Company financial data Financial data

Quarter (USD) Jun 19 Mar 19 Jun 18 Mar 18
Revenue 39.32M 27.41M 48.14M 36.55M
Net income -3.99M -8.72M -13.12M -4.8M
Diluted EPS -0.08 -0.16 -0.25 -0.09
Net profit margin -10.14% -31.82% -27.25% -13.14%
Operating income 686K -2.74M -4.91M -3.53M
Net change in cash -2.28M -7.28M 913K -13.93M
Cash on hand 4.12M 6.4M 13.68M 12.76M
Cost of revenue 9.8M 7.36M 11.47M 9.33M
Annual (USD) Dec 17 Dec 16 Dec 15 Dec 14
Revenue 67.25M 66.88M 44.25M 33.74M
Net income -15.19M -11.99M 6.67M 5.25M
Diluted EPS -0.28 -0.23 -0.07 0.09
Net profit margin -22.59% -17.92% 15.07% 15.56%
Operating income -11.8M 2.54M -3.19M 3.91M
Net change in cash -39.31M -21.19M -71.69M
Cash on hand 26.69M 66.01M 87.19M 158.88M
Cost of revenue 39.88M 32.19M 22.94M 16.95M

Financial data from Teligent earnings reports

Financial report summary

  • We have a history of losses and cannot assure you that we will become profitable. As a result, we may have to cease operations and liquidate our business.
  • We rely on a limited number of customers for a large portion of our revenues.
  • Due to our dependence on a limited number of products, our business will be materially adversely affected if these products do not perform as well as expected.
  • The pharmaceutical industry in which we operate is intensely competitive. We are particularly subject to the pressures of direct competition. For example, the competition we encounter may have a negative impact upon the prices we may charge for our products, the market share of our products and our revenue and profitability.
  • As our competitors introduce their own generic equivalents of our generic pharmaceutical products, our revenues and gross margin from such products may decline, potentially rapidly.
  • Our strategy depends on our ability to successfully develop and launch new pharmaceutical products ahead of our competitors.
  • If pharmaceutical companies are successful in limiting the use of generics through their legislative, regulatory and other efforts, sales of our generic products may be adversely impacted.
  • Our generics business also faces increasing competition from brand-name manufacturers that do not face any significant regulatory approval or other barriers to enter into the generics market.
  • We may need to raise additional capital that will be required to operate and grow our business, and we may not be able to raise capital on terms acceptable to us or at all.
  • Our business and operations have experienced rapid growth, and if we do not appropriately manage any future growth, our business will be adversely affected.
  • Sales of our products may continue to be adversely affected by the continuing consolidation of our distribution network and the concentration of our customer base. The result of such developments could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.
  • We face intense competition in the consumer products business.
  • Lack of availability, issues with quality or significant increases in the cost of raw materials used in manufacturing our products could adversely impact our profit margins and operating results.
  • We depend on a limited number of suppliers for API. Generally, only a single source of API is qualified for use in each product due to the costs and time required to validate a second source of supply. Changes in API suppliers must usually be approved by the FDA through a Prior Approval Supplement to each ANDA.
  • Incidents related to hazardous materials could materially adversely affect our reputation, business, financial condition, operating results and cash flows.
  • We are subject to stringent regulatory requirements related to environmental protection and hazardous waste disposal. Failure to adhere to such requirements could harm our business and results of operations.
  • We are subject to extensive government regulation by the FDA and other federal, state and local regulatory authorities that increases our costs and could prevent us from marketing or selling our products.
  • We are subject to extensive government regulation by Health Canada and other federal, state provincial/territorial and local regulatory authorities that increases our costs and could prevent us from marketing or selling our products.
  • Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
  • Our global operations expose us to certain risks, including challenges associated with political and economic instability, major hostilities and acts of terrorism.
  • Violations of cGMP and other government regulations could have a material adverse effect on our reputation, business, financial condition and results of operations.
  • During our efforts to expand our existing manufacturing facility, as well as potentially select and build out an additional manufacturing facility, we could experience business interruptions, as well as incur significant capital expenditures to complete the expansions, which may have a material adverse effect on our business, financial position and results of operations.
  • We could experience business interruptions at our manufacturing facility, which may have a material adverse effect on our business, financial position and results of operations.
  • We are currently in the process of expanding our manufacturing facilities. Any delays in the expansion process or in the receipt of certain regulatory approvals in connection therewith could have a material adverse effect on our business and results of operations.
  • Our reporting and payment obligations related to our participation in federal health care programs, including Medicare and Medicaid, are complex and often involve subjective decisions that could change. Any failure to comply with those obligations could subject us to investigation, penalties, and sanctions.
  • Our policies regarding returns, allowances and chargebacks, failure to supply penalties and marketing programs adopted by wholesalers may reduce revenues in future fiscal periods.
  • We are subject to federal and state healthcare fraud and abuse and false claims laws and may be subject to related litigation brought by the government or private individuals.
  • Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.
  • Even after our products receive regulatory approval, such products may not achieve expected levels of market acceptance.
  • Product recalls could harm our business.
  • We are susceptible to product liability claims that may not be covered by insurance and could require us to pay substantial sums.
  • The manufacture and storage of pharmaceutical and other products are subject to inherent risk.
  • The testing required for the regulatory approval of our products is conducted by independent third parties. Any failure by any of these third parties to perform this testing properly and in a timely manner may have an adverse effect upon our ability to obtain regulatory approvals.
  • The failure to obtain, maintain or protect patents, trade secrets, know-how and other intellectual property could impact our ability to compete effectively.
  • Our product offerings and our customers’ products may infringe on the intellectual property rights of third parties.
  • Significant balances of intangible assets, including goodwill, are subject to impairment testing and may result in impairment charges, which may materially and adversely affect our results of operations and financial condition.
  • We may not be able to fully realize the expected benefits from the acquisition of certain products and/or companies.
  • Our approved products may not achieve commercialization at levels of market acceptance that allow us to achieve profitability, which could have a material adverse effect on our business, financial position and results of operations.
  • Future acquisitions and investments could disrupt our business and harm our financial condition and operating results.
  • We may become involved in legal proceedings from time to time which may result in losses, damage to our business and reputation and place a strain on our internal resources.
  • Our business and operations would suffer in the event of system failures.
  • Compliance with ongoing post-marketing obligations for our approved ANDAs, NDAs, NDSs, and ANDSs may uncover new safety information that could give rise to a product recall, updated warnings, or other regulatory actions that could have an adverse impact on our business.
  • Economic conditions could severely impact us.
  • Adverse conditions in the economy and disruption of financial markets could negatively impact our customers and therefore our results of operations.
  • If we are unable to hire additional qualified personnel, our ability to grow our business may be harmed.
  • We have identified material weaknesses in our internal control over financial reporting, and if we are unable to satisfy regulatory requirements relating to internal controls, our stock price could suffer.
  • We have identified material weaknesses in our internal control over financial reporting, which could continue to impact negatively our ability to report our results of operations and financial condition accurately and in a timely manner.
  • Currency fluctuations and changes in exchange rates could adversely affect our business, financial condition, results of operations, cash flows, and/or common stock price.
  • The Company is exposed to market risk from fluctuations in currency exchange rates.
  • Our ability to use our net operating loss carry forwards and certain other tax attributes may be limited.
  • Shares of our common stock can be relatively illiquid which may affect the trading price of our common stock.
  • We have not paid dividends to our common stockholders in the past nor do we expect to pay dividends in the foreseeable future, and any return on investment may be limited to potential future appreciation on the value of our common stock.
  • If we fail to comply with the reporting obligations of the Exchange Act and Section 404 of the Sarbanes-Oxley Act of 2002, or if we fail to achieve and maintain adequate disclosure controls and procedures and internal control over financial reporting, our business results of operations and financial condition, and investors’ confidence in us, could be materially adversely affected.
  • Our principal stockholders, directors and executive officers own a significant percentage of our stock and will be able to exercise significant influence over our affairs.
  • Due to the concentration of common stock owned by significant stockholders, the sale of such stock might adversely affect the price of our common stock.
  • Our stock price is, and we expect it to remain, volatile and subject to wide fluctuations, which may make it difficult for stockholders to sell shares of common stock at or above the price for which they were acquired.
  • If we fail to meet the continued listing standards of the Nasdaq Global Select Market, our common stock could be delisted and our liquidity and stock price could suffer.
  • We may not have the ability to raise the funds necessary to settle conversions of the Notes, purchase the Notes as required pursuant to the terms of the indenture governing the Notes or pay the redemption price for any Notes we redeem, and our future debt may contain limitations on our ability to pay cash upon conversion or repurchase of the Notes.
  • To the extent we issue shares of our common stock to satisfy all or a portion of our conversion obligation, conversions of the Notes will dilute the ownership interest of our existing stockholders, including holders who had previously converted their Notes.
  • Our ability to make scheduled payments and satisfy our other obligations pursuant to our Senior Credit Facility depends on our future operating performance and on economic, financial, competitive, and other factors beyond our control.
  • Restrictive covenants in our Senior Credit Facilities may interfere with our ability to obtain additional advances under existing credit facilities or to obtain new financing or to engage in other business activities.
  • We will continue to have the ability to incur debt; if we incur substantial additional debt, these higher levels of debt may affect our ability to pay the principal of and interest on the Notes and the Senior Credit Facilities.
Management Discussion
  • We had a net loss of $4.0 million, or $0.08 per share, for the three months ended June 30, 2019 ("Current Period"), compared to a net loss of $13.1 million, or $0.25 per share, for the three months ended June 30, 2018 ("Prior Period"). Product Sales, net, include Company Product Sales and Contract Manufacturing Sales, as follows:
Content analysis ?
H.S. sophomore Avg
New words: Amerisource, avoid, batch, Bergen, bringing, comparison, consecutive, counter, denied, earmarked, elevate, entertain, favorable, inbound, maker, movement, notice, Oklahoma, outright, pilot, Police, recent, request, successful, swing, tangible, tranche, unsecured, unsolicited, wholly
Removed: additionally, assessed, assurance, error, Medicaid, Medicare, modified, retrospective, specifically, volume